\uff5e \u81e8\u5e8a\u958b\u767a\u696d\u52d9\u306e\u30d7\u30ed\u30d5\u30a7\u30c3\u30b7\u30e7\u30ca\u30eb\u306e95%\u306f\u73fe\u5728\u3001\u60a3\u8005\u4e2d\u5fc3\u306e\u81e8\u5e8a\u8a66\u9a13\u306e\u305f\u3081\u306e<\/p>\n
\u9023\u643a\u3055\u308c\u305f\u30c7\u30b8\u30bf\u30eb\u57fa\u76e4\u306e\u69cb\u7bc9\u306b\u6ce8\u529b \uff5e<\/p>\n
<\/p>\n
2021\u5e7411\u670816\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
<\/p>\n
Veeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b Veeva) \u304c\u5b9f\u65bd\u3057\u305f\u8abf\u67fb\u300cDigital Clinical Trials Survey Report<\/a><\/strong>\u300d\u306b\u3088\u308b\u3068\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3068\u533b\u85ac\u54c1\u958b\u767a\u696d\u52d9\u53d7\u8a17\u6a5f\u95a2\uff08CRO\uff09\u306f\u60a3\u8005\u4e2d\u5fc3\u306e\u30da\u30fc\u30d1\u30fc\u30ec\u30b9\u306a\u5206\u6563\u578b\u81e8\u5e8a\u8a66\u9a13\u306b\u5411\u3051\u3066\u524d\u9032\u3059\u308b\u305f\u3081\u306b\u3001\u30c7\u30b8\u30bf\u30eb\u30c8\u30e9\u30f3\u30b9\u30d5\u30a9\u30fc\u30e1\u30fc\u30b7\u30e7\u30f3\u3092\u52a0\u901f\u3055\u305b\u3066\u3044\u307e\u3059\u3002\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306f\u3001\u30b3\u30ed\u30ca\u798d\u306b\u304a\u3051\u308b\u5206\u6563\u578b\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u6025\u901f\u306a\u5c0e\u5165\u306b\u8d77\u56e0\u3059\u308b\u696d\u52d9\u4e0a\u306e\u8ab2\u984c\u3092\u6539\u5584\u3057\u3001\u5358\u306a\u308b\u5206\u6563\u5316\u3092\u8d85\u3048\u3066\u767a\u5c55\u3059\u308b\u81e8\u5e8a\u8a66\u9a13\u30e2\u30c7\u30eb\u3078\u3068\u9032\u5316\u3055\u305b\u308b\u305f\u3081\u306b\u65ad\u56fa\u305f\u308b\u884c\u52d5\u3092\u53d6\u3063\u3066\u3044\u308b\u3053\u3068\u304c\u3001\u3053\u306e\u4e16\u754c\u898f\u6a21\u306e\u65b0\u305f\u306a\u8abf\u67fb\u306b\u3088\u308a\u660e\u3089\u304b\u306b\u306a\u308a\u307e\u3057\u305f\u3002 (\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059\u3002\u539f\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u304b\u3089\u304a\u8aad\u307f\u3044\u305f\u3060\u3051\u307e\u3059\u3002)<\/p>\n <\/p>\n \u73fe\u5728\u3001\u307b\u3068\u3093\u3069\uff0887%\uff09\u306e\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u306f\u3001\u4f55\u3089\u304b\u306e\u5206\u6563\u578b\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u3092\u5229\u7528\u3057\u3066\u304a\u308a\u3001\u305d\u306e\u5272\u5408\u306f\u30b3\u30ed\u30ca\u798d\u4ee5\u524d\u3088\u308a\u308259\u30dd\u30a4\u30f3\u30c8\u5897\u3048\u3066\u3044\u307e\u3059\u3002\u3053\u3046\u3057\u305f\u5909\u5316\u306b\u4f34\u3044\u3001\u4f01\u696d\u306e\u81e8\u5e8a\u958b\u767a\u74b0\u5883\u306b\u306f\u5e73\u57474\u7a2e\u985e\u306e\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u304c\u65b0\u305f\u306b\u8ffd\u52a0\u3055\u308c\u3001\u305d\u306e\u7d50\u679c\u3001\u30c7\u30fc\u30bf\u53ce\u96c6\u3084\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u9593\u306e\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u306b\u554f\u984c\u304c\u751f\u3058\u3001\u81e8\u5e8a\u8a66\u9a13\u306e\u54c1\u8cea\u3084\u30b9\u30d4\u30fc\u30c9\u306b\u5f71\u97ff\u304c\u51fa\u3066\u3044\u307e\u3059\u3002<\/p>\n \u4eca\u56de\u306e\u8abf\u67fb\u7d50\u679c\u304b\u3089\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u304c\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u65bd\u3092\u30b9\u30ea\u30e0\u5316\u3057\u3001\u88ab\u9a13\u8005\u3084\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306e\u4f53\u9a13\u3092\u5411\u4e0a\u3055\u305b\u308b\u305f\u3081\u306b\u3001\u305d\u3046\u3057\u305f\u8ab2\u984c\u3078\u306e\u5bfe\u5fdc\u7b56\u3092\u8b1b\u3058\u3066\u3044\u308b\u3053\u3068\u304c\u308f\u304b\u308a\u307e\u3059\u3002\u307b\u307c\u3059\u3079\u3066\uff0895%\uff09\u306e\u56de\u7b54\u8005\u306f\u3001\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u9593\u306e\u60c5\u5831\u5171\u6709\u3084\u30b3\u30e9\u30dc\u30ec\u30fc\u30b7\u30e7\u30f3\u306e\u6539\u5584\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306e\u30b5\u30dd\u30fc\u30c8\u306e\u5f37\u5316\u3001\u9023\u643a\u3055\u308c\u305f\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u306b\u3088\u308b\u30b5\u30a4\u30ed\u89e3\u6d88\u306e\u305f\u3081\u306b\u3001\u7d71\u5408\u5316\u3055\u308c\u305f\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u57fa\u76e4\u306e\u69cb\u7bc9\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\u3053\u308c\u306b\u3088\u308a\u3001\u88ab\u9a13\u8005\u5411\u3051\u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3068\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u306e\u696d\u52d9\u3001\u81e8\u5e8a\u8a66\u9a13\u30c7\u30fc\u30bf\u304c\u96c6\u7d04\u3055\u308c\u3001\u3088\u308a\u8fc5\u901f\u3067\u52b9\u7387\u7684\u306a\u30a8\u30f3\u30c9\u30c4\u30fc\u30a8\u30f3\u30c9\u306e\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u306e\u5b9f\u73fe\u306b\u3064\u306a\u304c\u308b\u3067\u3057\u3087\u3046\u3002<\/p>\n \u88ab\u9a13\u8005\u3084\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3068\u306e\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u306e\u6539\u5584\u306f\u91cd\u8981\u306a\u53d6\u308a\u7d44\u307f\u3067\u3042\u308a\u3001\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u30e2\u30c7\u30eb\u3078\u306e\u79fb\u884c\u3092\u4fc3\u9032\u3059\u308b\u8981\u56e0\u3068\u3057\u3066\u5e38\u306b\u6319\u3052\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u533b\u7642\u6a5f\u95a2\u306e\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306e\u5c0e\u5165\u4e0d\u8db3\uff0870%\uff09\u3084\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5acc\u3044\u306e\u88ab\u9a13\u8005\u306e\u8ca0\u62c5\u5897\u5927\uff0850%\uff09\u306a\u3069\u3001\u5206\u6563\u578b\u81e8\u5e8a\u8a66\u9a13\u306b\u4f34\u3046\u4e3b\u306a\u8ab2\u984c\u306b\u5bfe\u51e6\u3059\u308b\u305f\u3081\u306b\u5927\u304d\u306a\u5909\u5316\u304c\u8d77\u304d\u3066\u3044\u307e\u3059\u3002\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u306f\u3001\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u306b\u3088\u308b\u533b\u7642\u6a5f\u95a2\u306e\u30b5\u30dd\u30fc\u30c8\u3092\u5f37\u5316\u3057\u3066\u7d19\u30d9\u30fc\u30b9\u306e\u30d7\u30ed\u30bb\u30b9\u3092\u6392\u9664\u3059\u308b\u3053\u3068\u3067\u3001\u30b7\u30fc\u30e0\u30ec\u30b9\u306a\u81e8\u5e8a\u8a66\u9a13\u5b9f\u65bd\u3068\u30c7\u30fc\u30bf\u30d5\u30ed\u30fc\u3092\u53ef\u80fd\u306b\u3057\u3001\u88ab\u9a13\u8005\u304c\u8a66\u9a13\u306b\u53c2\u52a0\u3057\u3084\u3059\u304f\u306a\u308b\u3088\u3046\u5229\u4fbf\u6027\u3092\u9ad8\u3081\u308b\u305f\u3081\u306b\u6295\u8cc7\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n Veeva Systems\u306eVault R&D\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3067\u3042\u308bJim Reilly\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u30b3\u30e1\u30f3\u30c8\u3057\u3066\u3044\u307e\u3059\u3002\u300c\u5206\u6563\u578b\u30a2\u30d7\u30ed\u30fc\u30c1\u306f\u81e8\u5e8a\u8a66\u9a13\u306b\u30dd\u30b8\u30c6\u30a3\u30d6\u306a\u5909\u5316\u3092\u3082\u305f\u3089\u3057\u3066\u3044\u307e\u3059\u304c\u3001\u3088\u308a\u8fc5\u901f\u3067\u8cbb\u7528\u5bfe\u52b9\u679c\u306e\u9ad8\u3044\u81e8\u5e8a\u8a66\u9a13\u3092\u5b9f\u73fe\u3059\u308b\u305f\u3081\u306b\u306f\u3001\u3055\u3089\u306a\u308b\u53d6\u308a\u7d44\u307f\u304c\u5fc5\u8981\u3067\u3059\u3002\u771f\u306e\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u306f\u81e8\u5e8a\u8a66\u9a13\u306e\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u3092\u3064\u306a\u304e\u3001\u88ab\u9a13\u8005\u3001\u8a66\u9a13\u5b9f\u65bd\u533b\u7642\u6a5f\u95a2\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u306e\u81e8\u5e8a\u8a66\u9a13\u4f53\u9a13\u3092\u5411\u4e0a\u3055\u305b\u308b\u3067\u3057\u3087\u3046\u3002\u300d<\/p>\n \u30ec\u30dd\u30fc\u30c8\u5168\u6587\u306f\u3053\u3061\u3089<\/a><\/strong>\u3088\u308a\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9\u3044\u305f\u3060\u3051\u307e\u3059\u3002<\/p>\n <\/p>\n <\/p>\n \u3010<\/strong>Veeva Systems<\/strong>\u793e\u306b\u3064\u3044\u3066\u3011<\/strong> <\/p>\n \u8abf\u67fb\u306e\u30cf\u30a4\u30e9\u30a4\u30c8 – Veeva Digital Clinical Trials Survey Report<\/strong><\/p>\n Veeva Digital Clinical Trials Survey Report\u306f\u3001\u4e16\u754c\u5404\u5730\u306e280\u540d\u3092\u8d85\u3048\u308b\u81e8\u5e8a\u958b\u767a\u696d\u52d9\u306e\u30d7\u30ed\u30d5\u30a7\u30c3\u30b7\u30e7\u30ca\u30eb\u306e\u7d4c\u9a13\u8ac7\u3068\u610f\u898b\u3092\u96c6\u3081\u308b\u3053\u3068\u306b\u3088\u308a\u3001\u5206\u6563\u578b\u30a2\u30d7\u30ed\u30fc\u30c1\u304c\u81e8\u5e8a\u8a66\u9a13\u306b\u3082\u305f\u3089\u3059\u6a5f\u4f1a\u3068\u5f71\u97ff\u3092\u8abf\u67fb\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8abf\u67fb\u5831\u544a\u66f8\u3067\u306f\u3001\u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u6226\u7565\u306e\u52d5\u5411\u3001\u5f97\u3089\u308c\u305f\u6559\u8a13\u3001\u91cd\u8981\u306a\u6210\u529f\u8981\u56e0\u3092\u793a\u3057\u307e\u3059\u3002<\/p>\n \u30b3\u30ed\u30ca\u798d\u306b\u304a\u3051\u308b\u81e8\u5e8a\u8a66\u9a13\u5206\u6563\u30e2\u30c7\u30eb\u306e\u52a0\u901f<\/strong><\/p>\n \u5206\u6563\u578b\u81e8\u5e8a\u8a66\u9a13\u3078\u306e\u6025\u901f\u306a\u79fb\u884c\u306b\u8d77\u56e0\u3059\u308b\u696d\u52d9\u4e0a\u306e\u8ab2\u984c\u306e\u5897\u52a0<\/strong><\/p>\n \u30c7\u30b8\u30bf\u30eb\u81e8\u5e8a\u8a66\u9a13\u3078\u306e\u79fb\u884c\u306b\u3088\u308b\u81e8\u5e8a\u8a66\u9a13\u306e\u54c1\u8cea\u6539\u5584\u3068\u8fc5\u901f\u5316<\/strong><\/p>\n \u5206\u6563\u578b\u81e8\u5e8a\u8a66\u9a13\u306b\u95a2\u3059\u308b\u81e8\u5e8a\u958b\u767a\u696d\u52d9\u306e\u30d7\u30ed\u30d5\u30a7\u30c3\u30b7\u30e7\u30ca\u30eb\u306e\u58f0<\/strong><\/p>\n <\/p>\n \u3010Forward-looking Statements\u3011 Veeva\u304c\u5b9f\u65bd\u3057\u305f\u8abf\u67fb\u300cDigital Clinical Trials Survey Report\u300d\u306b\u3088\u308a\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3068CRO\u306f\u60a3\u8005\u4e2d\u5fc3\u306e\u30da\u30fc\u30d1\u30fc\u30ec\u30b9\u306a\u5206\u6563\u578b\u81e8\u5e8a\u8a66\u9a13\u306b\u5411\u3051\u3066\u524d\u9032\u3059\u308b\u305f\u3081\u306b\u3001DX\u3092\u52a0\u901f\u3055\u305b\u3066\u3044\u308b\u3053\u3068\u304c\u660e\u3089\u304b\u306b\u3002<\/p>\n","protected":false},"author":131,"featured_media":46474,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322,341],"tags":[],"class_list":["post-46464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","category-case-study"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46464"}],"collection":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=46464"}],"version-history":[{"count":6,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46464\/revisions"}],"predecessor-version":[{"id":50854,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/46464\/revisions\/50854"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media\/46474"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=46464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=46464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=46464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nVeeva Systems\u793e\u306f\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u3092\u63d0\u4f9b\u3059\u308b\u30b0\u30ed\u30fc\u30d0\u30eb\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f01\u696d\u304b\u3089\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067\u30011,100\u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u306b\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f\u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u306b\u30b3\u30df\u30c3\u30c8\u3059\u308b\u69d8\u3005\u306a\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002\u30d1\u30d6\u30ea\u30c3\u30af\u30fb\u30d9\u30cd\u30d5\u30a3\u30c3\u30c8\u30fb\u30b3\u30fc\u30dd\u30ec\u30fc\u30b7\u30e7\u30f3\u4f01\u696d\u3068\u3057\u3066Veeva\u306f\u3001\u304a\u5ba2\u69d8\u3084\u5f93\u696d\u54e1\u3001\u63d0\u643a\u4f01\u696d\u3001\u682a\u4e3b\u3001\u30b5\u30fc\u30d3\u30b9\u63d0\u4f9b\u696d\u754c\u3092\u542b\u3080\u3059\u3079\u3066\u306e\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u306e\u5229\u76ca\u30d0\u30e9\u30f3\u30b9\u3092\u4fdd\u3064\u3053\u3068\u306b\u30b3\u30df\u30c3\u30c8\u3057\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001https:\/\/veeva.com\/jp\/<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n\n
\n
\n
\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2021.This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"